echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Qianjiang pharmaceutical and TnI company of the United States launched the new drug application of "Zhongzhu 1018" in China

    Qianjiang pharmaceutical and TnI company of the United States launched the new drug application of "Zhongzhu 1018" in China

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On the evening of March 10, Hubei Qianjiang Pharmaceutical Co., Ltd., a subsidiary of China Pearl holdings, signed a supplementary cooperation agreement with TnI Biotechnology Co., Ltd

    (TnI company for short)

    Both parties confirm that: we will immediately start the basic and clinical trials of new drug application of "Zhongzhu 1018" in China, and Qianjiang pharmaceutical will inject start-up funds into the joint management account within one month after the supplementary agreement takes effect, At the same time, TnI company of the United States provides all research materials, data and achievements of "Zhongzhu 1018" in China for its registration and application in the United States

    The use of the funds in the joint management account is signed off by Qianjiang pharmaceutical and the authorized person of TnI company of the United States

    In the process of Qianjiang pharmaceutical's registration and application of new drugs in China, TnI company of the United States arranges research experts for technical guidance at any time, "Zhongzhu 1018" The latest research progress and achievements in the United States are shared with Qianjiang pharmaceutical without reservation and serve as the test basis for registration and application in China; when Qianjiang pharmaceutical applies for registration in China, the indications are the same as those in the United States; after obtaining the production approval, Qianjiang pharmaceutical is responsible for the production and sales of "Zhongzhu 1018" in mainland China

    "Zhongzhu 1018", a TnI company in the United States, has been used to treat pancreatic cancer in phase I and phase II clinical trials

    The FDA review meeting of the United States agreed that TnI company of the United States should develop freeze-dried dosage forms, take the form of intravenous injection, agree with the results of phase I and phase II clinical trials, agree to hold phase II clinical summary meeting again after the relevant pharmaceutical and pharmacological toxicology test data are supplemented and improved, and approve "Zhongzhu 1018" to conduct phase III clinical trials in the United States

    In October 2012, Qianjiang pharmaceutical, a subsidiary of China Pearl holdings, signed a cooperation agreement with TnI Biotechnology Co., Ltd

    (US) to jointly develop preclinical research on blood, bone marrow hematopoietic system cancer and cancer patients' immune recovery anticancer drugs

    In order to avoid risks, both parties agree to determine further cooperation after the US enters phase III clinical

    In principle, after TnI is admitted to phase III clinical practice, China and the United States will further promote phase III clinical practice in China

    In view of the cooperation agreement between China food and Drug Administration and FDA, the drugs approved by the us to enter phase III clinical will enjoy a green channel in China

    At present, the cooperation project between the two sides in China is still in the laboratory stage

    Previously, it was rumoured that once TnI bio obtained the approval of FDA's phase III plan for pancreatic cancer, TnI bio will give the final budget to Hubei Qianjiang pharmaceutical

    Under the agreement of both parties, Hubei Qianjiang pharmaceutical will be responsible for the preparation of the fund

    It is estimated that the cost of phase III plan will be 30 million to 40 million US dollars, and Hubei Qianjiang pharmaceutical will also get the exclusive franchise of the drug in China

    It is understood that TnI company has possessed the new drugs (including the intellectual property rights, patent technology and license currently possessed by "Zhongzhu 1018") for the treatment of cancer in blood and bone marrow hematopoietic system and the immune recovery of cancer patients, and obtained the results in preclinical stage, and has conducted preclinical research with Qianjiang pharmaceutical

    Zhongzhu holding said that the purpose of holding hands with TnI of the United States is to let Qianjiang pharmaceutical obtain the exclusive license of "Zhongzhu 1018" technology in China, and obtain the new drug certificate and production approval of "Zhongzhu 1018", a national first-class chemical, issued by China food and drug administration

    At the same time, the cooperation between the two sides is also conducive to strengthening the research and development of drugs and increasing the drug reserves of Qianjiang pharmaceutical

     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.